The mission of our Institute is to advance new fundamental understanding of the molecular, cellular and etiological basis of human diseases. We integrate molecular medicine research, Technology Centre and Biobank Infrastructure “under one roof” and thereby promote translational research and adoption of personalised medicine in health care. As part of the Nordic EMBL Partnership for Molecular Medicine, we follow the principles of EMBL partnerships. This means aiming to scientific excellence and establishing mechanisms for independent scientific review of the research activities; scientific integrity and good scientific practice; high level, regular international evaluations with consequences for tenure and funding, as well as commitment to significant levels of staff turnover.

The research at FIMM focuses on two main areas:

In 2013, there were altogether fifteen research groups at FIMM, including six FIMM-EMBL groups and three FiDiPro Professors. The disease areas of interest for the research groups cover cancer, cardiovascular disease, diabetes, neurology, neuropsychiatric diseases and viral infections. In 2013, FIMM was strengthened by one more group leader, when FiDiPro Professor Leif Groop from Lund University, Sweden, supported by the Academy of Finland, started at FIMM. Furthermore, Samuli Ripatti was promoted as a Professor of Biometry. He is now the first FIMM-EMBL group leader having been promoted to a full professorship.

Team Science

At FIMM, we emphasize team science with several groups together attacking major challenges for society. We have three grand challenge programmes, which all made significant progress during the year. First, the human genomics and predictive health finished the assembly of 3325 Finnish genomes and started pilots to apply the information in diagnostics and health care. Read more »

Second, the individualized cancer therapy grand challenge finished its first study in acute myeloid leukaemia, and expanded work to other tumours and attracted major industrial funding. Third, the digital medicine/systems pathology initiative also progressed, largely as a result of IMI and company support. Multiplexed staining to identify immune cells in tumours was started. Fimmic Lts spin-off company was launched.

FIMM grand challenge programmes:

Research Was Evaluated and Found to Be Excellent

The FIMM five-year Evaluation was carried out in May 2013 by an international Evaluation Committee comprising of eight experts of the SAB (Scientific Advisory Board) of FIMM, EMBL (European Molecular Biology Laboratory), as well as invited external experts. The evaluation focused on the research groups. The Evaluation Committee stated in its report that in a remarkably short time FIMM has succeeded to build up a successful research programme and a technology platform at a quality level, ¬†equalling the best in the world. Research activities, including research training, were evaluated very positively as well. Director General of EMBL, Professor Iain Mattaj, introduced the Report and gave a positive summary of FIMM progress at the EMBL Council Meeting in June 2013. Read the whole report »

Evaluation Committee visited FIMM in May 2013

Team Work Resulted in High-Quality Publications

Altogether, FIMM researchers published 167 peer-reviewed articles in 2013. The mean impact factor of these publications was 8.55. Up to 23 of the publications were published in journals having an impact factor above 15. More than half of the publications were fruits of an international collaboration. The whole list of publications for 2013 can be seen here.